SG11202010154UA - Method for enhancing the suppressive properties of treg cells - Google Patents
Method for enhancing the suppressive properties of treg cellsInfo
- Publication number
- SG11202010154UA SG11202010154UA SG11202010154UA SG11202010154UA SG11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA SG 11202010154U A SG11202010154U A SG 11202010154UA
- Authority
- SG
- Singapore
- Prior art keywords
- enhancing
- treg cells
- suppressive properties
- suppressive
- properties
- Prior art date
Links
- 230000002708 enhancing effect Effects 0.000 title 1
- 210000003289 regulatory T cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806330.5A GB201806330D0 (en) | 2018-04-18 | 2018-04-18 | Engineered regulatory T cell |
| GBGB1806331.3A GB201806331D0 (en) | 2018-04-18 | 2018-04-18 | Method |
| PCT/GB2019/051098 WO2019202323A1 (en) | 2018-04-18 | 2019-04-17 | Method for enhancing the suppressive properties of treg cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202010154UA true SG11202010154UA (en) | 2020-11-27 |
Family
ID=66286535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202010154UA SG11202010154UA (en) | 2018-04-18 | 2019-04-17 | Method for enhancing the suppressive properties of treg cells |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20210145884A1 (ja) |
| EP (2) | EP3781672A1 (ja) |
| JP (3) | JP7436383B2 (ja) |
| KR (1) | KR20210003810A (ja) |
| CN (2) | CN112004924A (ja) |
| AU (2) | AU2019254824A1 (ja) |
| CA (2) | CA3098128A1 (ja) |
| GB (3) | GB2587988B (ja) |
| IL (1) | IL278016A (ja) |
| SG (1) | SG11202010154UA (ja) |
| WO (2) | WO2019202322A1 (ja) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201915359D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Engineered regulatory t cell |
| TW202227631A (zh) * | 2020-11-09 | 2022-07-16 | 英商圭爾醫療有限公司 | 冷凍保存經工程化之調節t細胞(tregs)之方法 |
| US20220169687A1 (en) * | 2020-11-10 | 2022-06-02 | Kyverna Therapeutics, Inc. | Method for treating disease using foxp3+cd4+ t cells |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| WO2023048275A1 (ja) * | 2021-09-27 | 2023-03-30 | 国立大学法人京都大学 | Ｔ細胞の製造方法 |
| WO2023111594A1 (en) | 2021-12-17 | 2023-06-22 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| US20230210900A1 (en) * | 2022-01-04 | 2023-07-06 | Kyverna Therapeutics, Inc. | Methods for treating autoimmune diseases |
| WO2023180690A1 (en) | 2022-03-22 | 2023-09-28 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| WO2023214182A1 (en) * | 2022-05-05 | 2023-11-09 | Quell Therapeutics Limited | Method for maintaining suppressive activity of regulatory t cells |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8053197B2 (en) * | 2004-07-30 | 2011-11-08 | Oregon Health & Science University | Methods for detecting and treating autoimmune disorders |
| US20100135974A1 (en) * | 2007-01-31 | 2010-06-03 | Yeda Research And Development Co. Ltd. | Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease |
| WO2013107413A1 (zh) * | 2012-01-19 | 2013-07-25 | 中国科学院上海巴斯德研究所 | 磷酸化途径相关因子在调控调节性t细胞功能中的应用 |
| US10093901B2 (en) * | 2013-05-10 | 2018-10-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Use of specific regulatory T-cells to induce immune tolerance |
| GB201322430D0 (en) * | 2013-12-18 | 2014-02-05 | Immunocore Ltd | T cell receptors |
| US10414812B2 (en) | 2015-02-16 | 2019-09-17 | The Trustees Of The University Of Pennsylvania | Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/neu (ERBB2) receptor protein |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| EP3263595A1 (en) * | 2016-06-30 | 2018-01-03 | Medizinische Hochschule Hannover | Fusion protein for use in the treatment of hvg disease |
| US20200330515A1 (en) * | 2017-10-17 | 2020-10-22 | The General Hospital Corporation | Methods and compositions relating to engineered regulatory t cells |
| GB201915359D0 (en) * | 2019-10-23 | 2019-12-04 | Ucl Business Ltd | Engineered regulatory t cell |
-
2019
- 2019-04-17 EP EP19719599.3A patent/EP3781672A1/en active Pending
- 2019-04-17 US US17/048,587 patent/US20210145884A1/en active Pending
- 2019-04-17 JP JP2020556864A patent/JP7436383B2/ja active Active
- 2019-04-17 US US17/048,239 patent/US20210079425A1/en active Pending
- 2019-04-17 GB GB2018103.8A patent/GB2587988B/en active Active
- 2019-04-17 CA CA3098128A patent/CA3098128A1/en active Pending
- 2019-04-17 EP EP19719600.9A patent/EP3781673A1/en active Pending
- 2019-04-17 KR KR1020207032996A patent/KR20210003810A/ko active Search and Examination
- 2019-04-17 AU AU2019254824A patent/AU2019254824A1/en active Pending
- 2019-04-17 JP JP2020556883A patent/JP7391038B2/ja active Active
- 2019-04-17 SG SG11202010154UA patent/SG11202010154UA/en unknown
- 2019-04-17 AU AU2019256783A patent/AU2019256783A1/en active Pending
- 2019-04-17 CA CA3105303A patent/CA3105303A1/en active Pending
- 2019-04-17 CN CN201980026673.5A patent/CN112004924A/zh active Pending
- 2019-04-17 WO PCT/GB2019/051097 patent/WO2019202322A1/en unknown
- 2019-04-17 CN CN201980041068.5A patent/CN112334571B/zh active Active
- 2019-04-17 GB GB2300916.0A patent/GB2611707A/en not_active Withdrawn
- 2019-04-17 WO PCT/GB2019/051098 patent/WO2019202323A1/en unknown
- 2019-04-17 GB GB2300872.5A patent/GB2611498B/en active Active
-
2020
- 2020-10-13 IL IL278016A patent/IL278016A/en unknown
-
2023
- 2023-11-21 JP JP2023197319A patent/JP2024026127A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB2611498B (en) | 2023-07-19 |
| CN112334571A (zh) | 2021-02-05 |
| EP3781672A1 (en) | 2021-02-24 |
| AU2019254824A1 (en) | 2020-11-26 |
| GB2611498A (en) | 2023-04-05 |
| CN112004924A (zh) | 2020-11-27 |
| JP2021520834A (ja) | 2021-08-26 |
| GB2587988B (en) | 2023-05-31 |
| CA3105303A1 (en) | 2019-10-24 |
| AU2019256783A1 (en) | 2020-10-22 |
| IL278016A (en) | 2020-11-30 |
| WO2019202322A1 (en) | 2019-10-24 |
| US20210079425A1 (en) | 2021-03-18 |
| GB202018103D0 (en) | 2020-12-30 |
| GB2611707A (en) | 2023-04-12 |
| CN112334571B (zh) | 2024-06-25 |
| KR20210003810A (ko) | 2021-01-12 |
| JP7391038B2 (ja) | 2023-12-04 |
| GB2587988A (en) | 2021-04-14 |
| GB202300916D0 (en) | 2023-03-08 |
| JP7436383B2 (ja) | 2024-02-21 |
| JP2021520831A (ja) | 2021-08-26 |
| EP3781673A1 (en) | 2021-02-24 |
| CA3098128A1 (en) | 2019-10-24 |
| WO2019202323A1 (en) | 2019-10-24 |
| US20210145884A1 (en) | 2021-05-20 |
| GB202300872D0 (en) | 2023-03-08 |
| JP2024026127A (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2587988B (en) | Method for enhancing the suppressive properties of Treg cells | |
| EP3602672A4 (en) | SYSTEM AND METHOD FOR SURFACE TREATMENT OF SOLID ELECTROLYTES | |
| EP3408641A4 (en) | METHOD AND DEVICE FOR MULTILOOKING CHARACTERIZATION | |
| EP3432320A4 (en) | SOLID ELECTROLYTE, AND METHOD OF MANUFACTURING THE SAME | |
| EP3188741A4 (en) | Compositions and methods for the treating an inflammatory disease or disorder | |
| IL276131A (en) | Methods for using car t cells | |
| EP3483266A4 (en) | METHOD FOR EXAMINING THE INTERIOR OF THE ORAL CAVITY | |
| IL266454B (en) | Implant and method of creating the implant | |
| EP3766984A4 (en) | DETERMINATION PROCESS | |
| IL283948A (en) | Methods for treating depression | |
| EP3586343A4 (en) | TITANIUM MOLYBDATE AND METHOD FOR MANUFACTURING ITEM | |
| EP3632905A4 (en) | METHOD FOR PRODUCING N-ACYL-ORTHO-AMINOBENZAMIDE | |
| EP3242640A4 (en) | Hybrid device for surgical aortic repair and method of using the same | |
| ZA202101685B (en) | Method and system for quantum-resistant hashing scheme | |
| EP3158915A4 (en) | Endoscope system and white balance adjustment method for same | |
| IL272559A (en) | A method for the preparation of 4-(heptafluoro-2-propyl) aniline | |
| PL3611119T3 (pl) | Wysuwny pomost przeładunkowy oraz sposób użytkowania tego pomostu | |
| EP3734277A4 (en) | PROCESS FOR EVALUATING A MEDICINAL PRODUCT | |
| ZA201807469B (en) | Method for identifying snoring | |
| EP3602036A4 (en) | PROCESS FOR DETERMINATION OF FILMOGENOUS AMINES | |
| IL275612A (en) | Method for preparing bap or ba cells | |
| EP3380844A4 (en) | PROCESS FOR CHECKING THE PRIMARY STRUCTURE OF PROTEIN | |
| EP3729851A4 (en) | PROCESS FOR DETECTING A POSSIBLE TAKING OF SCREENSHOTS | |
| PL3609839T3 (pl) | Sposób zagospodarowania fosfogipsów | |
| EP3547176A4 (en) | APPARATUS AND METHOD FOR DETERMINING CIRCULATORY DISEASE POTENTIAL |